Resumen: Live attenuated and killed whole-cell vaccines (WCVs) offer promising vaccination strategies against tuberculosis. A number of WCV candidates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or related mycobacterial species are in various stages of preclinical or clinical development. In this review, we discuss the vaccine candidates and key factors shaping the development pathway for live and killed WCVs and provide an update on progress. Idioma: Inglés DOI: 10.1093/infdis/jiw228 Año: 2016 Publicado en: JOURNAL OF INFECTIOUS DISEASES 214, 5 (2016), 659-664 [22 pp] ISSN: 0022-1899 Factor impacto JCR: 6.273 (2016) Categ. JCR: IMMUNOLOGY rank: 23 / 150 = 0.153 (2016) - Q1 - T1 Categ. JCR: MICROBIOLOGY rank: 15 / 124 = 0.121 (2016) - Q1 - T1 Categ. JCR: INFECTIOUS DISEASES rank: 7 / 84 = 0.083 (2016) - Q1 - T1 Factor impacto SCIMAGO: 3.931 - Infectious Diseases (Q1) - Immunology and Allergy (Q1)